Phaseline

Companies › Chengdu Qingshan Likang Pharmaceutical

Chengdu Qingshan Likang Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
amino acid (15) peritoneal dialysis solution
Peritoneal dialysis solution containing 15 essential and non-essential amino acids
–Phase 4End Stage Renal Disease (ESRD)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06597201amino acid (15) peritoneal dialysis solutionPhase 4End Stage Renal Disease (ESRD)GenitourinaryJun 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience Hope Medicine (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.